Henry Schein, Inc. $HSIC Shares Sold by Fiduciary Management Inc. WI

Fiduciary Management Inc. WI decreased its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 6.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,293,597 shares of the company’s stock after selling 146,742 shares during the period. Henry Schein makes up approximately 1.9% of Fiduciary Management Inc. WI’s investment portfolio, making the stock its 18th largest holding. Fiduciary Management Inc. WI’s holdings in Henry Schein were worth $173,350,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. increased its position in Henry Schein by 212.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 67,181 shares of the company’s stock worth $5,078,000 after purchasing an additional 45,701 shares during the period. Kettle Hill Capital Management LLC acquired a new position in Henry Schein during the 3rd quarter worth approximately $14,158,000. Tudor Investment Corp ET AL acquired a new position in Henry Schein during the 3rd quarter worth approximately $15,375,000. Snyder Capital Management L P increased its position in Henry Schein by 18.6% during the 3rd quarter. Snyder Capital Management L P now owns 1,334,364 shares of the company’s stock worth $88,562,000 after purchasing an additional 209,123 shares during the period. Finally, SG Americas Securities LLC increased its position in Henry Schein by 171.9% during the 4th quarter. SG Americas Securities LLC now owns 820,698 shares of the company’s stock worth $62,028,000 after purchasing an additional 518,914 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

Insider Buying and Selling

In related news, Director Kurt P. Kuehn sold 2,844 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total value of $224,562.24. Following the sale, the director owned 15,420 shares of the company’s stock, valued at approximately $1,217,563.20. This represents a 15.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Thomas C. Popeck sold 1,355 shares of the company’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $72.79, for a total value of $98,630.45. Following the completion of the sale, the chief executive officer directly owned 86,182 shares in the company, valued at approximately $6,273,187.78. The trade was a 1.55% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.89% of the company’s stock.

Henry Schein Stock Performance

HSIC opened at $77.45 on Friday. The stock has a market cap of $8.82 billion, a P/E ratio of 23.40, a P/E/G ratio of 1.49 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.36 and a quick ratio of 0.75. The stock’s 50 day simple moving average is $74.70 and its 200 day simple moving average is $75.93. Henry Schein, Inc. has a 1-year low of $61.94 and a 1-year high of $89.29.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. The business had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The company’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities analysts anticipate that Henry Schein, Inc. will post 5.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on HSIC shares. Wells Fargo & Company boosted their target price on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Leerink Partners reiterated a “market perform” rating on shares of Henry Schein in a research report on Monday, March 9th. Barrington Research set a $97.00 target price on Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. boosted their target price on Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, Morgan Stanley reiterated an “underweight” rating and set a $64.00 target price (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $86.83.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.